The global pharmaceutical industry experienced a 47% drop in company filings mentions of social responsibility in Q3 2023 compared with the previous quarter, with the highest share accounted for by Merck with 121% year-on-year increase, according to GlobalDataâ€™s analysis of over 532 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, social responsibility was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of industrial automation and space economy, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Merck had the greatest increase in references for social responsibility in Q3 2023, compared with the previous quarter. GlobalData identified 320 social responsibility-related sentences in the company's filings - 7% of all sentences - and an increase of 121% in Q3 2023 compared with Q3 2022. Dr. Reddy's Laboratoriesâ€™s mentions of social responsibility rose by 431% to 191 and Sun Pharmaceutical Industriesâ€™s by 48% to 108 and Bristol-Myers Squibbâ€™s by 5800% to 59 and Ciplaâ€™s by 63% to 57.
GlobalDataâ€™s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for social responsibility in Q3 2023 was 112.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.